Navigation Links
FDA Approves Ferriprox to Treat Patients with Excess Iron in the Body
Date:10/14/2011

the level of a liver enzyme that may be indicative of tissue or liver damage at unsafe amounts.

The most serious side effect seen in about two percent of patients treated with Ferriprox was the development of agranulocytosis, a serious and potentially life-threatening reduction in the number of granulocytes (a type of white blood cell that fights infection).

The therapy is being approved under the FDA's accelerated approval program, designed to provide patients with earlier access to promising new drugs followed by further studies to confirm the drug's clinical benefit.

The accelerated approval program allows the agency to approve a drug to treat a serious disease based on clinical data showing that the drug has an effect on an endpoint that is reasonably likely to predict a clinical benefit to patients, or on an effect on a clinical endpoint other than survival or irreversible morbidity (illness).

ApoPharma has agreed to several post-marketing requirement and commitments. One commitment includes further study of the use of Ferriprox in patients with sickle cell disease who have transfusional iron overload.

Earlier this year, the U.S. Department of Health and Human Services (HHS) launched the Sickle Cell Disease (SCD) Initiative bringing together HHS agencies to enhance the quality and quantity of SCD data, develop best practice guidelines and quality of care metrics, improve health care delivery and coordination of care for patients with SCD, facilitate approval of new medical products, and expand research on SCD.  The post-marketing requirement for further study of Ferriprox aligns with the goals of the SCD Initiative.

Ferriprox is marketed by ApoPharma Inc. of Toronto.

For more information:

FDA: Office of Hematology and Oncology Products
http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm091745.htm

FDA: Spotlight o
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014 /PRNewswire-iReach/ -- Inc. ... Inc. for the third straight year, No. 349 ... an exclusive ranking of the nation,s fastest-growing private ... at the most important segment of the economy—America,s ... Dell, Domino,s Pizza, LinkedIn, Zillow, and many other ...
(Date:8/21/2014)... Aug. 21, 2014  Zacks.com announces the list of stocks ... Research analysts discuss the latest news and events impacting stocks ... include the Hewlett-Packard (NYSE: HPQ - Free Report ), IBM ... (NYSE: SB - Free Report ), GlaxoSmithKline plc (NYSE: ... (NYSE: FI - Free Report ). Today, ...
(Date:8/21/2014)... , Aug. 21, 2014 InfinityQS International, ... Manufacturing Intelligence , today announces Infusion Chicago, ... event will be held Oct. 9-10, 2014, at ... designed to showcase the necessity for implementing a ... and Manufacturing Intelligence to gain insight into production ...
Breaking Medicine Technology:Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 2The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 3The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 4The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 5The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 6The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 7The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 8The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 9The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 10The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 11InfinityQS to Host Manufacturing Intelligence Conference in Chicago 2
... PRINCETON, N.J. , June 14 Covance Inc. (NYSE: ... Company,s 30th Annual Growth Stock Conference on Wednesday, June 16, 2010 ... the presentation at www.covance.com .  In order to register and download any ... , , ...
... June 14 MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) ... Cheshire, England to manage its planned Phase IIb clinical trial ... candidate for treatment of primary multiple sclerosis-related fatigue (PMSF). , ... In an earlier Phase IIa study, MCT-125 ...
Cached Medicine Technology:MultiCell Hires Clinical Research Organization to Manage MCT-125 Phase IIb Clinical Trial 2MultiCell Hires Clinical Research Organization to Manage MCT-125 Phase IIb Clinical Trial 3MultiCell Hires Clinical Research Organization to Manage MCT-125 Phase IIb Clinical Trial 4
(Date:8/21/2014)... (PRWEB) August 21, 2014 AVEC ... to announce the addition of Kerry Gillespie as ... of healthcare management experience, Gillespie brings an extremely ... multiple executive management positions with prominent industry leading ... served as President of Triad Isotopes, Inc. a ...
(Date:8/21/2014)... 21, 2014 The costs for maintaining pet health ... according to new insurance industry studies. The Quotes Pros company is ... locate affordable plans from all 50 states at http://quotespros.com . ... $50 for a routine visit or complex surgery can use the ... of the system will be asked to provide a zip code ...
(Date:8/21/2014)... 21, 2014 Recently, Van Uden ... patients. Alternative medicine is on the rise and ... According to The Fiscal Times, young people are ... conventional medicine. , The Fiscal Times published an ... are embracing alternative medicine. The article can be ...
(Date:8/21/2014)... 21, 2014 Pulmonary Hypertension Association ... Education Forum for PH patients and families to ... Pulmonary Hypertension Association – the country’s leading ... to prevent and cure pulmonary hypertension (PH) – ... functioning of the heart and can lead right ...
(Date:8/21/2014)... Garden Grove, California (PRWEB) August 21, 2014 ... announce the initial plans for entertainment and programming for ... Streets Event.” On Sunday, October 12, 2014, from 11 ... will be closed to all cars and the downtown ... workshops and activities, curated by Community Arts Resources (CARS), ...
Breaking Medicine News(10 mins):Health News:Kerry Gillespie Appointed as Chief Executive Officer of AVEC Health Solutions 2Health News:Pet Insurance Finder for 50 States Launched at Insurance Website Online 2Health News:Van Uden Center Sees Growth in Alternative Medicine 2Health News:Pulmonary Hypertension Association Goes On the Road to Houston With an Education Forum for PH Patients and Families to Help Fight Rare Lung Disease 2Health News:Pulmonary Hypertension Association Goes On the Road to Houston With an Education Forum for PH Patients and Families to Help Fight Rare Lung Disease 3Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 2Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 3Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 4
... offer tips to avoid mowing-related hazards , SATURDAY, ... such a common summertime activity that many people forget ... warn. , Each year in the United States, about ... mower-related accidents, according to the U.S. Consumer Product Safety ...
... Nearly 600 Kidney-Friendly Recipes to Meet Kidney Care Needs for ... DaVita Inc. (NYSE: DVA ), a leading provider ... disease (CKD), offers fathers and their families the opportunity to ... nearly 600 kidney-friendly recipes available on DaVita.com ...
... visit Healthy Athletes Village and hand out awards , ... to catch Summer Games action at the University of ... Village today from 9:30-10 a.m. and will hand out awards ... Field. , , Healthy Athletes is an initiative designed ...
... D.C. The amount of time imaging equipment is ... rates President Obama and the Medicare Payment Advisory Commission ... according to data recently collected by the Radiology Business ... in radiology. The RBMA data, which consist ...
... -- Cell Therapeutics, Inc. (the "Company" or "CTI") (Nasdaq ... separate concurrent fixed price exchange offers (each, an "Exchange Offer" ... the approximately $118.9 million outstanding principal amount of five series ... expired at 5:00 p.m., New York City time, on Tuesday, ...
... Boston, MA -- As President Obama prepares to sign ... oversight of the tobacco industry, a new study from ... tobacco manufacturers have continually changed the ingredients and the ... changes have exceeded acceptable product variance guidelines. The result, ...
Cached Medicine News:Health News:Don't Get Lazy About Lawn-Mower Safety 2Health News:DaVita.com Provides Easy Recipes to Plan Your Father's Day Dinner 2Health News:DaVita.com Provides Easy Recipes to Plan Your Father's Day Dinner 3Health News:Last Day of Special Olympics Minnesota's 2009 Summer Games 2Health News:Last Day of Special Olympics Minnesota's 2009 Summer Games 3Health News:Data: Actual imaging use far below president's recommended 95 percent utilization rate for Medicare 2Health News:Data: Actual imaging use far below president's recommended 95 percent utilization rate for Medicare 3Health News:Data: Actual imaging use far below president's recommended 95 percent utilization rate for Medicare 4Health News:Cell Therapeutics Announces Final Results of its Fixed Price Exchange Offers for Any and All of its $118.9 Million Convertible Notes Outstanding 2Health News:Cell Therapeutics Announces Final Results of its Fixed Price Exchange Offers for Any and All of its $118.9 Million Convertible Notes Outstanding 3Health News:Study finds that tobacco companies changed design of cigarettes without alerting smokers 2
LiquichekCardiac Markers Plus Control LT is a premium, comprehensive cardiac assessment control with many analytes and long stability....
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
... Siemens' ACUSON brand, the new Antares ... ultrasound system that provides highly upgradeable ... enhanced workflow efficiencies, and user-friendly ergonomics. ... builds upon the advanced workflow and ...
Medicine Products: